A phase Ib clinical trial NCT03528642 examined CB-839/telaglenastat safety and anti-tumor activity in combination with radiation therapy and temozolomide in patients with IDH-mutated diffuse or anaplastic astrocytoma. This evidence concerns the gene IDH1 and neoplasm.